PP_1170x120_10-25-21

Dan Leonard

Should patients with same condition bear different costs?

Should patients with same condition bear different costs?

Suppose two customers who are both diagnosed with rheumatoid arthritis approach your pharmacy counter. The first line of treatment for rheumatoid arthritis works effectively for the first customer, but it doesn’t work well in managing the second customer’s symptoms. The second customer’s doctor recommends another treatment that is more effective for her, yet it is

Health policy in 2017: Innovation, value and access

Health policy in 2017: Innovation, value and access

For the past two years, organizations in the private and public sectors have been working to develop tools to support value-based health care and evidence-based medical decision making. In 2017, these efforts will take on an even greater urgency, driven by the ongoing, accelerating progress of biopharmaceutical research and development. As more — and more

Purdue Pharma joins National Pharmaceutical Council

Purdue Pharma joins National Pharmaceutical Council

WASHINGTON — Purdue Pharma L.P. has become a member of health policy research group The National Pharmaceutical Council (NPC). NPC said Dr. Tracy Mayne, head of medical affairs strategic research at Purdue Pharma, will serve as the pharmaceutical company’s representative on the NPC board of directors. “NPC’s research and activities are helping to drive the discussion

Mallinckrodt joins National Pharmaceutical Council

Mallinckrodt joins National Pharmaceutical Council

WASHINGTON — Mallinckrodt Pharmaceuticals has become a member of the National Pharmaceutical Council (NPC). The health policy research organization said Thursday that Steven Romano, senior vice president and chief scientific officer at Mallinckrodt, will serve as the company’s representative on the NPC board of directors. “We are pleased that Mallinckrodt has joined us in support

Health care stakeholders need to talk

Health care stakeholders need to talk

With the heated rhetoric about Obamacare on the presidential campaign trail, congressional hearings focused on drug costs and news reports about these debates, is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and appropriate treatments and encourage future innovation? We believe

Access to medications, adherence go hand in hand

Access to medications, adherence go hand in hand

If the lack of medication adherence were an easy problem to solve, then everyone would be taking their medicines as directed, there would be no need for iPhone apps or electronic pill bottle reminders, patient health outcomes would be improved, and overall health care costs would be lower because of reduced complications or ­hospitalizations. Yet

ACOs spearhead shift to value-based care

ACOs spearhead shift to value-based care

Recently, U.S. Health and Human Services (HHS) Secretary Sylvia Burwell announced a lofty goal of tying 50% of all traditional Medicare payments to alternative payment models, such as accountable care organizations (ACOs) or bundled payment arrangements, by the year 2018. In announcing these ambitious goals, Burwell stated, “Whether you are a patient, a provider, a